Hansa Medical publishes the Annual Report for 2017
Hansa Medical's Annual Report for 2017 is now available on the company’s website, www.hansamedical.com.
Visit our Annual report 2017 site at http://hansamedical.com/annual-report/2017/
The Annual Report is posted to shareholders and other stakeholders who specifically request it. For further information please contact the company by telephone +46 46-16 56 70 or e-mail firstname.lastname@example.org.
The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person stated below on April 11, 2018 at 8.00 CET.
For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, IdeS, is a proprietary antibody-degrading enzyme currently in late- stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing with the objective of treating relapsing autoimmune diseases and cancer. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.